Introduction
============

Deep venous thrombosis (DVT) is one of the most common vascular diseases and is associated with high mortality and complex therapeutic processes ([@b1-ijmm-45-06-1735]). Thrombolytics and interventional therapies are still the mainstream treatments for DVT, but they are limited by a low cure rate and a high postoperative recurrence rate ([@b2-ijmm-45-06-1735]). The current therapeutic methods are restricted, especially regarding the prolonged time for diagnosis and treatment ([@b3-ijmm-45-06-1735]). Considering the complex mechanisms and various regulatory factors of DVT, studies on DVT have focused on the underlying regulatory genes, providing a valuable foundation for the diagnosis and treatment of DVT ([@b4-ijmm-45-06-1735]-[@b6-ijmm-45-06-1735]).

Krüppel-like factor 15 (Klf15), a transcriptional regulatory factor, is involved in various pathophysiological processes, such as cell differentiation, apoptosis and tumor formation, which are closely related to cardiovascular diseases such as hypertension, atherosclerosis and coronary heart disease ([@b4-ijmm-45-06-1735]). Klf15 is widely expressed in tissues and organs, especially in the heart, liver, kidneys and skeletal muscles ([@b7-ijmm-45-06-1735]). Lu *et al* ([@b8-ijmm-45-06-1735]) reported that similarly to other members of the KLF family, Klf15 inhibits NF-κB activation in vascular smooth muscle by interacting with p300 (Klf15-p300), thereby inhibiting down-stream target genes and inflammatory responses. Moreover, the expression level of Klf15 significantly decreased in mouse aortic smooth muscle cells treated with the oxidized component POVPC and human atherosclerotic tissues, which revealed that Klf15 plays a key role in the formation of atherosclerosis ([@b7-ijmm-45-06-1735],[@b8-ijmm-45-06-1735]). Studies revealing the relationship and the genetic interaction between DVT and Klf15 are urgently needed. Therefore, transcriptome analysis of Klf15 in a mouse inferior vena cava (IVC) thrombosis model was performed to identify the functions of Klf15 and its relationship with the regulatory process and formation of DVT.

High-throughput sequencing, or next-generation sequencing, is a novel genomic research technique characterized by high data output and involves RNA sequencing (RNA-seq); high-throughput sequencing can be utilized in the analysis of various transcriptional and functional regions ([@b9-ijmm-45-06-1735]). Strikingly, extensive data resources can be provided via high-throughput sequencing to enable the identification and screening of target genes or differentially expressed genes (DEGs) in the whole genome, which is important for analyzing the regulatory relationships between genes and disease pathogenesis ([@b10-ijmm-45-06-1735]).

Previous studies have investigated the role of Klf15 in atherosclerosis ([@b8-ijmm-45-06-1735]) and vascular smooth muscle cells (VSMCs) ([@b11-ijmm-45-06-1735]). Klf15 is a regulator of VSMC proinflammatory activation and overexpression of Klf15 can protect vascular endothelial cells against dysfunction ([@b12-ijmm-45-06-1735]). Although the pathogeneses of atherosclerosis and DVT are different, endothelial cells are important for both atherosclerosis and DVT. Disruption of the endothelium and the release of plaque constituents into the lumen of the blood vessel can trigger arterial thrombosis ([@b13-ijmm-45-06-1735],[@b14-ijmm-45-06-1735]). Abnormal blood flow, altered properties of the blood itself and changes in the endothelium can trigger venous thrombosis. In contrast to what is observed in atherosclerosis, venous endothelial cells remain intact, but their dysfunction can trigger DVT ([@b15-ijmm-45-06-1735]). According to our knowledge, no reports have studied Klf15 in DVT. The research on Klf15 in atherosclerosis prompted the present study to hypothesize that Klf15 can protect against DVT by affecting venous endothelial cells. Preliminary experiments were performed in C57/BL/6 mice and the results showed that inhibition of Klf15 induced DVT. In this study, the regulatory relationship and genetic interactions between DVT and Klf15 were investigated, revealing a new regulatory mechanism in a mouse model that could contribute to the diagnosis and treatment of DVT.

Materials and methods
=====================

Mouse and animal studies
------------------------

The current study was performed with 40 C57BL/6 female mice (age, 8-10 weeks; weight, 20±3 g) that were purchased from the SPF animal laboratory of Kunming Medical University (Kunming, China). The mice were divided into four groups (n=10), according to a random grouping design. Then, the mice were fed at the experimental center of the SPF animal laboratory at Kunming Medical University with free access to food and water, a constant temperature of 21-25°C, a humidity level at 50-65%, under a 12-h light/dark cycle with proper ventilation. Next, a 2-3 week feeding period was conducted until the mice reached ≥25 g per mouse. The mice were observed twice daily to monitor their health and behavior. All animal experiments were performed following approval from the Animal Experiment and Ethics Committee of Kunming Medical University.

Generation of IVC thrombus in C57BL/6 mice
------------------------------------------

Once the weight of the mice exceeded 25 g, modeling of IVC thrombi in C57BL/6 mice was performed in each mouse except the Blank group. Mice were separated into four groups: The Blank group, the DVT group, the Klf15-NC group and the Klf15-small interfering (si)RNA group. The Blank and DVT groups were first generated, and mice in the DVT group underwent an operation to generate an IVC thrombus by utilizing a string to induce artificial stenosis of the IVC for thrombus formation ([@b16-ijmm-45-06-1735]). IVC thrombosis in mice was first modeled. After 24 h, the thrombi were acquired. During the perioperative period, the mice were monitored twice daily and they did not appear to be in distress or to exhibit obvious behavioral abnormalities. After the IVC thrombi were collected for further investigation, no other procedures were performed on the mice. Isoflurane was used as the inhaled agent to produce general anesthesia in mice. During the perioperative period of the experiment, the inhalant anesthetic isoflurane was utilized to induce and maintain general anesthesia to minimize animal pain and suffering and limit the discomfort that can accompany scientific research. Isoflurane was first used at 2% for induction and then at 1-1.5% for maintenance. Mice that have undergone IVC removal are likely to experience great pain and distress; thus, euthanasia was considered as the humane option. Euthanasia was conducted 24 h after the IVC thrombus operation. The mice were first anesthetized with 5% isoflurane until they stopped moving or appeared to be unconscious. Next, cervical dislocation was conducted, separating the cervical vertebrae from the skulls of the mice. An array of criteria was used to confirm the success of euthanasia, including arrest of pulse and breathing, lack of corneal reflex and inaudibility of respiratory sounds and heartbeat sounds upon examination with a stethoscope. The same process was performed for the IVC of the Klf15-NC and Klf15-siRNA groups, and there was an additional caudal vein injection with 0.9% normal saline (NS) in the Klf15-NC group and with Klf15 siRNA: 5′-CCT GTG AAG GAG GAA CAT T-3′ (Guangzhou RiboBio Co., Ltd.; 10 nmol per mouse) in the Klf15-siRNA group, which was performed 24 h before the operation. A total of 40 C57BL/6 mice were used in the present experiment, 36 of which were euthanized by cervical dislocation under anesthesia; four died due to hemorrhagic shock. The success of DVT modeling was judged by direct observations of the weights of the thrombi and vessels collected from the mice. In the present experiments, when 7-8 mm thrombi or vessels from mice were examined, most of the thrombi weighed \>10 mg and most of the vessels weighed \<10 mg.

RNA isolation and RNA-seq
-------------------------

On the basis of morphological experiments, thrombi in the IVC of mice and the vessels themselves were collected for examination. According to the manufacturer\'s protocol, RNA was extracted with TRIzol Reagent at 4°C. RNA purity was determined using a NanoPhotometer spectrophotometer (IMPLEN) and the concentration was measured using a Qubit RNA Assay kit in a Qubit^®^ 2.0 Fluorometer (Thermo Fisher Scientific, Inc.). RNA integrity was assessed using the RNA Nano 6000 Assay kit of the Bioanalyzer 2100 system (Agilent Technologies, Inc.). Then, RNA degradation and contamination were monitored on 1% agarose gels. Furthermore, RNA purity was assessed using the RNA Nano 6000 Assay kit of the Bioanalyzer 2100 system (Agilent Technologies, Inc.). Thus, qualified RNA was used as a material for later analyses and provided samples for RNA-seq.

RNA-seq data and bioinformatics analysis
----------------------------------------

High-throughput sequencing was used to obtain and identify raw reads in samples. Further evaluation of the quality of the clean reads was performed to discard low-quality reads, which had either \>50% of bases with a Q value ≤20 or \>5% unrecognized sequences (\'N\'). After obtaining the high-quality clean reads, the reads were mapped to the human reference genome to enable downstream gene analysis.

For analysis of the expression levels of transcripts and the correlation of replicates, the fragments per kilobases per million mapped reads (FPKM) method was utilized in Pearson\'s correlation analysis to identify DEGs among each group of transcript sequences, which was determined by genetic length and the reads mapped to the human reference genome.

To detect the DEGs among the groups, DESeq2 was used, which provides statistical routines for determining differential expression in digital gene expression data using a model based on a negative binomial distribution. The resulting P-values were adjusted using Benjamini and Hochberg\'s approach for controlling the false discovery rate. Genes with an adjusted P\<0.05 according to DESeq2 were considered differentially expressed.

GO enrichment analysis of DEGs was implemented by the clusterProfiler R package 3.14.3 ([@b17-ijmm-45-06-1735]), in which the gene length bias was corrected. GO terms with corrected P\<0.05 were considered significantly enriched with DEGs. KEGG is a database resource used to elucidate the high-level functions and utilities of biological systems, such as the cell, organism and ecosystem, from molecular-level information, especially large-scale molecular datasets generated by genome sequencing and other high-throughput experimental technologies (<http://www.genome.jp/kegg/>). The clusterProfiler R package was used to test the statistical enrichment of DEGs in KEGG pathways.

qPCR analysis of DEGs
---------------------

For validation of the expression of genes and the consistency of these two comparisons, qPCR analysis of DEGs was conducted according to the manufacturer\'s protocol for Maxima^®^ SYBR-Green/ROX qPCR Master Mix (2X) (MBI Fermentas; Thermo Fisher Scientific, Inc.) on an ABI PRISM^®^ 7300HT system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: Initial denaturation at 95°C for 10 min (1 cycle), followed by denaturation at 95°C for 15 sec and annealing and extension at 60°C for 60 sec (40 cycles). The primer sequences were obtained using the 2^−∆∆Cq^ method ([@b8-ijmm-45-06-1735]) \[ABI DataAssist™ v3.0 software (Thermo Fisher Scientific, Inc.)\] and were as follows: KLF15 (77 bp) forward: 5′-CTT CCC TGA ATT TCT GTC-3**′** and reverse: 5′-ATT CTT CAA TCT CCT CCA-3′; Mmp12 (88 bp) forward: 5**′**-CAG CAT TCC AAT AAT CCA A-3**′** and reverse: 5**′**-GTA TGT CAT CAG CAG AGA-3**′**; Mmp13 (79 bp) forward: 5**′**-GTG ATG ATG ATG ATG ATG AC-3**′** and reverse: 5**′**-GCA GGA TGG TAG TAT GAT T-3**′**; Arg1 (71 bp) forward: 5**′**-AAC ACG GCA GTG GCT TTA-3**′** and reverse: 5**′**-TCA GTC CCT GGC TTA TGG-3**′**; Ccl2 (120 bp) forward: 5**′**-TGG GTC CAG ACA TAC ATT-3**′** and reverse: 5**′**-ACG GGT CAA CTT CAC ATT-3**′**; Fmo23 (88 bp) forward: 5**′**-GAG TCT GGG ACG ATG GCT AC-3**′** and reverse: 5**′**-GAG ATG GCG GTG GGT AAG-3**′**; heme oxygenase-1 (Hmox1) (88 bp) forward: 5**′**-TCA CAG ATG GCG TCA CTT-3**′**, and reverse: 5**′**-AGC GGT GTC TGG GAT GAG-3**′**; Mmp19 (113 bp) forward: 5**′**-GAT GCT GCC GTT TAC TCT-3**′** and reverse: 5**′**-GGT TGG GCT CTA CTC TGT T-3**′**; β-actin (87 bp) forward: 5**′**-TAT GGA ATC CTG TGG CAT C-3**′** and reverse: 5**′**-GTG TTG GCA TAG AGG TCT T-3**′**.

Statistical analysis
--------------------

Prism 7 (GraphPad Software, Inc.) was used for all statistical analyses. The results from mouse thrombi ([Figs. 1](#f1-ijmm-45-06-1735){ref-type="fig"} and [6](#f6-ijmm-45-06-1735){ref-type="fig"}) are presented as the mean ± SEM. The experiments were repeated three times. An unpaired two-tailed Student\'s t-test between two groups was used for statistical significance of differences analyzed. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Effect of Klf15 on thrombosis formation and the wet weight of the mouse thrombus
--------------------------------------------------------------------------------

Klf15 has been shown to be critical for the initiation and progression of vascular inflammation ([@b6-ijmm-45-06-1735]). In this study, to identify the effects of Klf15 on DVT, morphological experiments were conducted on mice with IVC thrombi, which were divided into four groups: The Blank group, the DVT group, the Klf15-NC group with 0.9% NS caudal vein injection and the Klf15-siRNA group with Klf15-siRNA caudal vein injection ([Table I](#tI-ijmm-45-06-1735){ref-type="table"}). The vessels were removed from the mice of Blank group. If there was a blood clot blocking the vein based on direct observations ([Fig. 1A](#f1-ijmm-45-06-1735){ref-type="fig"}), the clot was removed from the mouse for further examination ([Fig. 1B](#f1-ijmm-45-06-1735){ref-type="fig"}). The results revealed that the weight of the thrombus in the Klf15-siRNA group was increased compared with that in the Klf15-NC group. As shown in [Fig. 1C](#f1-ijmm-45-06-1735){ref-type="fig"}, compared with the Klf15-NC group, the Klf15-siRNA group with Klf15-siRNA injection (and thus with significantly reduced Klf15 expression) exhibited a significantly increased thrombus wet weight ([Fig. 1D](#f1-ijmm-45-06-1735){ref-type="fig"}). Thus, Klf15 is significantly associated with thrombus formation and weight.

RNA-seq results, data quality assessment and mapping
----------------------------------------------------

After performing the morphological experiments previously described, genetic analysis was conducted by RNA-seq, a method of high-throughput sequencing, to investigate transcriptional gene abundance and simultaneously study active regions of transcription.

Samples were divided into four groups: The Blank group, the DVT group, the Klf15-NC group (0.9% NS caudal vein injection) and the Klf15-siRNA group (Klf15-siRNA caudal vein injection). A total of \~25.8 and 28.1 million raw reads were collected from the DVT and Blank groups, respectively, while 29.6 and 30.3 million raw reads were obtained from the Klf15-NC and Klf15-siRNA groups, respectively. Then, further analysis was performed to obtain high-quality clean reads and the low-quality reads, which had either \>50% of bases with a Q value ≤20 or \>5% of unrecognized sequences (\'N\'), were discarded. Consequently, \~24.8 and 26.8 million high-quality clean reads were obtained from the DVT and Blank groups, respectively, 29.1 and 29.6 million high-quality clean reads were obtained from the Klf15-NC and Klf15-siRNA groups, respectively. Then, the clean reads were mapped to the human reference genome for downstream gene analyses. As a result, the rates of mapping for the DVT group and the Blank group were 89.40 and 90.22%, respectively, while the rates of mapping for the Klf15-NC group and the Klf15-siRNA group were 89.26 and 90.12%, respectively, which demonstrated the quality of the gene mapping. The results of the RNA-seq reads are listed in [Table II](#tII-ijmm-45-06-1735){ref-type="table"} and the mapping results are listed in [Table III](#tIII-ijmm-45-06-1735){ref-type="table"}. The high-quality reads for different groups were collected for further analyses.

Correlation analysis, principal component analysis (PCA) and clustering analysis
--------------------------------------------------------------------------------

To study the correlation and clustering of the transcript sequences, the FPKM method was used to evaluate the expression level of transcripts and the correlations between replicates, which were determined in each sample by utilizing the genetic length and the reads mapped to the human reference genome.

As shown in [Fig. 2A and B](#f2-ijmm-45-06-1735){ref-type="fig"}, except for the Blank 1 group with an R^2^≤0.8, Pearson\'s correlation analysis indicated that the distribution of the FPKM values were significantly consistent for all replicates compared with each group (R^2^≥0.8).

Furthermore, PCA was performed to evaluate the differences among groups and the consistency of samples within groups, which were expected to be distant from each other in different groups and clustered within the same group. The Blank 1 group, the DVT 1 group and the Klf15-siRNA 3 group were discarded, as these groups exhibited poor correlations with their own groups. Thus, clustering analysis was performed on groups of samples that were further separated into subgroups according to the PCA results: The Blank group (Blank 2 and Blank 3), the DVT group (DVT 2 and DVT 3), the Klf15-siRNA group (Klf15-siRNA2 and Klf15-siRNA5) and the Klf15-NC group (NC1, NC3 and NC4). The clustering analysis showed repeatable and correlative characteristics in the data. The results of the clustering analysis demonstrated gene expression differences between the Blank group and the DVT group and between the Klf15-siRNA group and the Klf15-NC group ([Fig. 2C and D](#f2-ijmm-45-06-1735){ref-type="fig"}).

Identification of DEGs
----------------------

For analysis of gene expression and the DEGs, data processing was conducted with the essential conditions of an adjusted P\<0.05 and log2-fold-change (FC) for the determination of gene regulation, which was log2FC\>1 for upregulated genes and log2FC\<-1 for down-regulated genes. In total, 2,206 DEGs were identified from the comparison of the DVT group and Blank group, including 1,330 upregulated genes and 876 downregulated genes, which are represented as red points and green points in the volcano plot, respectively ([Fig. 3A](#f3-ijmm-45-06-1735){ref-type="fig"}). Gene expression analysis also revealed 1,041 DEGs between the Klf15-siRNA group and the Klf15-NC group, with 235 upregulated genes and 806 downregulated genes ([Fig. 3B](#f3-ijmm-45-06-1735){ref-type="fig"}). The number of DEGs in each comparison is listed in [Table IV](#tIV-ijmm-45-06-1735){ref-type="table"}. As shown in [Table V](#tV-ijmm-45-06-1735){ref-type="table"}, the expression levels of these genes showed significant differences in the DVT group compared with in the Blank group and the genes mainly clustered into three gene families; there were five genes in the Mmp family, four genes in the IL family, and 13 genes in the chemokine family. The expression levels of Mmp3, Mmp8, Mmp9, Mmp13 and Mmp19 in the DVT group were significantly increased compared with those in the Blank group. The expression of Mmp12 was also increased in the DVT group when compared with the Blank group; however, this finding was not significant. Genes in the interleukin (IL) family, including Il-lr2, Il-la, Il-lb and Il-6, were expressed more highly in the DVT group than in the Blank group. Moreover, the expression levels of genes in the Cc and Cx families of the DVT group were higher than those of the Blank group, except the expression level of Cc121a, which was lower in the DVT group than in the Blank group.

As shown in [Table V](#tV-ijmm-45-06-1735){ref-type="table"}, there were four DEGs (Selp, Plaur, Hmoxl and Argl) that were detected from the comparison between the DVT group and the Blank group, which correlated with the previously obtained results.

Notably, two DEGs were identified, Fmo3 and Mmp19, that had not been previously detected in DVT and are listed in [Table V](#tV-ijmm-45-06-1735){ref-type="table"}.

As shown in [Table VI](#tVI-ijmm-45-06-1735){ref-type="table"}, three genes, Klf15, Mmp12 and Mmp13, showed higher expression in the Klf15-siRNA group than in the Klf15-NC group, except for the level of Klf15 itself due to the caudle vein injection of Klf15 siRNA in mice of the Klf15-siRNA group.

GO analysis of DEGs
-------------------

Previously in this study, DEGs were identified among different groups. Thus, GO enrichment analysis was performed to discover the biological processes of these DEGs, which demonstrated significant functions of gene expression in different groups. Then, the GO terms were divided into three categories: Biological process (BP), cellular component (CC) and molecular function (MF).

As shown in [Fig. 4A and B](#f4-ijmm-45-06-1735){ref-type="fig"}, the top 30 ranked GO terms of the comparison between the DVT group and the Blank group were selected for the bar graph and scatter plot. Consequently, \'leukocyte migration\' was the most significantly enriched term. Then, \'positive regulation of locomotion\', \'positive regulation of cell motility\' and \'positive regulation of cell migration\' accounted for the most enriched terms in the BP category. In addition, in [Fig. 4C and D](#f4-ijmm-45-06-1735){ref-type="fig"}, the top 30 ranked GO terms from the comparison of the Klf15-siRNA group and the Klf15-NC group showed that \'axon, postsynapse\' and \'presynapse\' were the most highly enriched terms. At the same time, \'the regulation of ion transmembrane transport\', \'signal release\' and \'modulation of synaptic transmission\' were abundant in both the CC category and the MF category.

The results of the GO analysis revealed the distribution of genes in different biological functions, from which information regarding DEGs that may be beneficial to further study could be obtained.

KEGG pathway analysis of DEGs
-----------------------------

To characterize the coordinative relations between genes and the roles of genes in biological functions, DEGs were analyzed by KEGG enrichment analysis, in which biochemical metabolic and signal transduction pathways were detected from the included DEGs.

The results in [Table VII](#tVII-ijmm-45-06-1735){ref-type="table"} revealed that 50 pathways with significant expression (P\<0.01) were identified in the comparison between the DVT group and the Blank group. In [Fig. 5A and B](#f5-ijmm-45-06-1735){ref-type="fig"}, the top 20 ranked pathways are listed in the bar graph and bubble diagram; numerous signal transduction pathways were notably enriched, including the \'HIF-1 signaling pathway\', \'Th17 cell differentiation\', \'the intestinal immune network for IgA production\', \'TNF signaling pathway\', \'cell adhesion molecules (CAMs)\', \'the PI3K-Akt signaling pathway\', \'ECM-receptor interactions\', \'the Jak-STAT signaling pathway\' and \'the IL-17 signaling pathway\'. Moreover, BP terms, including \'the cytokine-cytokine receptor interaction\', \'hematopoietic cell lineage\', \'Th17 cell differentiation\', \'CAM\', \'ECM-receptor interaction\', \'glycolysis/gluconeogenesis\', \'osteoclast differentiation\', \'*Staphylococcus aureus*infection\', \'Th1 and Th2 cell differentiation\', and \'complement and coagulation cascade terms\', were significantly enriched in the analysis.

In the comparison between the Klf15-siRNA group and the Klf15-NC group, 23 pathways with significant expression (P\<0.01) were identified and are listed in [Table VIII](#tVIII-ijmm-45-06-1735){ref-type="table"}. The top 20 ranked pathways are shown in [Fig. 5C and D](#f5-ijmm-45-06-1735){ref-type="fig"}. The results revealed that several signal transduction pathways were significantly enriched, including \'the PI3K-Akt signaling pathway\', \'the Hippo signaling pathway\', \'the cAMP signaling pathway\' and \'the relaxin signaling pathway\'. In addition, BP terms were identified; these terms included \'the cholinergic synapse\', \'neuroactive ligand-receptor interaction\', \'ECM-receptor interaction\', \'dopaminergic synapse\', \'nicotine addiction\', \'rheumatoid arthritis\', \'synaptic vesicle cycle\', \'taste transduction\', \'vascular smooth muscle contraction\', \'hypertrophic cardiomyopathy (HCM)\', \'serotonergic synapse\', \'mucin type O-glycan biosynthesis\', \'dilated cardio-myopathy (DCM)\' and \'protein digestion and absorption\' terms. Among these terms, the \'vascular smooth muscle contraction\', \'HCM\' and \'DCM\' terms provide crucial information regarding the roles of Klf15 in the formation and pathophysiological processes of vascular disease, especially DVT.

qPCR validation of DEGs
-----------------------

Next, to confirm the results of the DEG analyses, eight significant DEGs were selected from the RNA-seq results from the comparison of the DVT and Blank groups for further qPCR validation. As shown in [Fig. 6](#f6-ijmm-45-06-1735){ref-type="fig"}, the expression levels of Mmp12 and Mmp13 in the DVT group were significantly increased compared with those in the Blank group. The expression level of Klf15 in the DVT group decreased significantly compared with that in the Blank group. Moreover, the levels of Mmp 19, Arg1, Ccl2, Fmo3 and Hmox1 in the DVT group were all significantly increased compared with those in the Blank group, which demonstrated the correlation of the results.

Discussion
==========

DVT is one of the most common vascular diseases and has a high mortality rate ([@b1-ijmm-45-06-1735]). Nevertheless, the current diagnostic and therapeutic methods are limited ([@b18-ijmm-45-06-1735]). In current DVT studies, the mechanism and regulatory factors involved in the formation and pathological process of DVT should be investigated to provide a foundation for the diagnosis and treatment of DVT ([@b19-ijmm-45-06-1735]).

Klf15 was shown to be closely related to cardiovascular diseases such as hypertension, atherosclerosis and coronary heart disease ([@b20-ijmm-45-06-1735]). Klf15 is a transcriptional regulatory factor involved in various functions, including cell differentiation, apoptosis and tumor formation, and is expressed in various tissues and organs, including the heart, liver, and kidneys ([@b21-ijmm-45-06-1735]). Moreover, Klf15 plays a key role in the development of atherosclerosis ([@b12-ijmm-45-06-1735]). According to the authors\' preliminary experiments, it was found that Klf15 might also affect thrombosis. To promote knowledge about the relationship and genetic interaction between DVT and Klf15, this study was performed.

Numerous obstacles prevent the complete understanding of the pathology, diagnosis and treatment of DVT. The present study aimed to examine factors regulating the initiation and progression of DVT and factors related to effective and utilizable measures.

To the best of our knowledge, this is the first study to perform high-throughput sequencing in a mouse DVT model and to investigate the effect of Klf15 on DVT formation. The data and analyses in the current study suggest that pathways including TNF, PI3K-Akt, IL-17, Jak-STAT, NF-κB, and MAPK should be considered, as such pathways were correlated with the formation of thrombi according to the KEGG enrichment analysis of the DEGs between the DVT and Blank groups. Previous studies ([@b22-ijmm-45-06-1735],[@b23-ijmm-45-06-1735]) have reported that MAPK pathways are related to vascular endothelial venous thrombosis and our colleagues have suggested that resveratrol may exert an *in vitro*antithrombotic activity by inactivating MAPK signaling pathways ([@b24-ijmm-45-06-1735]). Moreover, KEGG analysis of the comparison of the Klf15-siRNA group and the Klf15-NC group indicated that PI3K-Akt play a central role in the regulatory pathway involved in DVT formation.

The DEGs revealed by these comparisons indicated the crucial role of certain genes in the regulation of DVT. In the comparison of the DVT and Blank groups, the identified genes ranged from members of the Mmp family, the IL family, and the chemokine family to Selp, Plaur, Hmox 1 and Arg1. Fonseca *et al* ([@b25-ijmm-45-06-1735]) indicated that Mmp plays a critical role in numerous cellular processes. Li *et al* ([@b26-ijmm-45-06-1735]) discovered that Mmp3 polymorphisms and upregulated protein expression in the Chinese Han population may provide new markers associated with the evaluation of DVT diagnosis and risk. Lenglet *et al* ([@b27-ijmm-45-06-1735]) performed a study on mice by subjecting their brains to ischemic stroke and revealed differentially expressed levels of Mmp family genes, including significantly upregulated expression of Mmp9, 10, and 13 and Timp1. Xiao *et al* ([@b28-ijmm-45-06-1735]) indicated that Mmp8 enhanced vascular smooth muscle cell (VSMC) proliferation and played an important role in neointima formation via ADAM10-, N-cadherin-, and β-catenin-mediated pathways. Mmp8 enhances VSMC proliferation, according to a study of WT and Mmp9-/- mice that underwent stasis venous thrombosis (VT) by ligation of the IVC. The tissues were harvested at different time points and the results showed that the midterm vein wall collagen content was regulated by Mmp9 ([@b28-ijmm-45-06-1735]). Thus, Mmp9 plays a role in both vein wall responses and late thrombus resolution. Quillard *et al* ([@b29-ijmm-45-06-1735]) found that Mmp13 prevailed over Mmp8 in collagen degradation in atheromata, thus identifying a selective target for plaque structure formation. Based on the current analysis and previous reports, the present study believes that the role of the MMP family in DVT deserves further study.

Genes in the IL family were identified, including Il-lr2, Il-la, Il-lb and Il-6, that showed higher expression in the DVT group than in the Blank group. Gupta *et al* ([@b30-ijmm-45-06-1735]) demonstrated the increased expression of NLRP3, caspase-1 and IL-1β in individuals with clinically established VT. van Minkelen *et al* ([@b31-ijmm-45-06-1735]) found that *IL1RN*-H5H5 carriership increases the risk of VT. Analyses of the DEGs in the chemokine families revealed that these DEGs had generally higher expression in the DVT group than in the Blank group, with the exception of some members mentioned in qPCR Validation of DEGs. Among those genes in the Cc and Cx families, a study of Cxcr2 was previously performed. Henke *et al* ([@b32-ijmm-45-06-1735]) found that normal DVT resolution involved Cxcr2-mediated neovascularization, collagen turn-over and fibrinolysis and that this process is probably primarily monocyte-dependent. Henke and Wakefield ([@b33-ijmm-45-06-1735]) indicated that early thrombus resolution primarily involves Cxcr2-associated plasmin activation and Mmp-9, while later resolution involves both Cxcr2- and Ccr2-mediated uPA cell influx and thrombus angiogenesis. According to the above reports and our data, inflammation plays an important role in the formation of DVT. The present study speculated that Ccl2, a downstream gene of Klf15, may be the key factor in the effects of Klf15 on DVT formation.

A study of the relationship between Hmox1 and DVT was conducted by Bean *et al* ([@b34-ijmm-45-06-1735]) who identified a critical cytoprotective enzyme encoded by the inducible Hmox1 gene with anti-inflammatory, antioxidant and anticoagulant activities in the vascular system. A (GT)n microsatellite located in the promoter of the Hmox1 gene influences the level of the response. Peng *et al* ([@b35-ijmm-45-06-1735]) stimulated HO-1 (Hmox1) production and revealed the inhibition of platelet-dependent thrombus formation in HO-1^−/−^ mice compared with that in WT mice, and this inhibition may represent an adaptive response mechanism to reduce platelet activation.

Bojic *et al* ([@b36-ijmm-45-06-1735]) conducted a study on mice regarding the relationships between the peroxisome proliferator-activated receptor (PPAR)δ agonist GW1516 in aortic inflammation and atherosclerosis via intervention by the PPARδ agonist; this study revealed that the progression of preestablished atherosclerosis was inhibited by aortic inflammation and attenuated by the progression of preestablished atherosclerosis. Furthermore, GW1516 intervention decreased the expression of aortic proinflammatory M1 cytokines, increased the expression of the anti-inflammatory M2 cytokine *Arg1* and attenuated the *iNos*/*Arg1*ratio. Samsoondar *et al* ([@b37-ijmm-45-06-1735]) performed hepatic gene expression analysis on *Ldlr*−*/*− mice fed a high-fat, high-cholesterol diet (42% kcal fat, 0.2% cholesterol) supplemented with bempedoic acid at 0, 3, 10 and 30 mg/kg body weight. These results showed that in the full-length aorta, bempedoic acid markedly suppressed cholesteryl ester accumulation, attenuated the expression of proinflammatory M1 genes and attenuated the *iNos*/*Arg1*ratio, which demonstrated that Ccl3 and Nos2 are marker genes for M1 macrophages and that Arg1 may be a marker gene for M2 macrophages. To the best of our knowledge, research and papers on the role of Arg1 in thrombosis are scarce but based on the current data, it suggests that Arg1 should be studied.

The present study first identified the critical roles of Fmo3 and Mmp19 in regulating DVT. Zhu *et al* ([@b38-ijmm-45-06-1735]) demonstrated that the microbe-dependent production of trimethylamine N-oxide (TMAO) contributes to the risk of thrombosis. Thus, a murine FeCl~3~-induced carotid artery injury model was established to confirm the impact of FMO3 suppression \[via antisense oligonucleotide (ASO) targeting\] and overexpression (as a transgene), which was examined by the plasma TMAO levels, platelet responsiveness and thrombosis potential. The present study demonstrated that host hepatic FMO3, the final product of the metaorganismal TMAO pathway, participates in diet- and gut microbiota-dependent changes in both platelet responsiveness and thrombosis potential *in vivo*([@b37-ijmm-45-06-1735]). Shih *et al* ([@b39-ijmm-45-06-1735]) treated WT and FMO3KO mice with control or FMO-3 ASOs. FMO-3-ASO treatment led to the same extent of lipid-lowering effects in the FMO3KO mice as it did in the WT mice, indicating off-target effects. This study revealed that both FMO3KO and WT mice fed a 0.5% choline diet showed a substantial reduction in both TMAO and *in vivo* thrombosis potential.

In conclusion, a transcriptome study consisting of two parts was performed to investigate the expression levels of Klf15 and other related genes in C57BL/6 mice with IVC thrombi for the first time. The experimental results indicated that 2,206 genes were differentially expressed between the DVT group and the Blank group, and 1,041 DEGs were identified by comparing the Klf15-siRNA group with the Klf15-NC group. The present study confirmed that Arg1, Ccl2 and Hmox1 are related to DVT, as previously identified, and new genes related to the formation of DVT were identified, including Fmo3 and Mmp19. Furthermore, to the best of our knowledge, the present study is the first to reveal that genes such as Mmp12 and Mmp13 are involved in the regulation of DVT; the current results obtained via comparison of the Klf15-siRNA group and the Klf15-NC group are especially revealing. Given the data obtained in the present experiments, it is speculated that Klf15 may play a role in DVT by regulating inflammatory genes, some members of the MMP family or other DEGs; however, this speculation needs to be confirmed in the future. In the next study, cell experiments, clinical experiments and additional animal experiments will be performed to confirm the role of Klf15 in DVT, including pathway regulation and whether DVT formation is regulated by Klf15 via Mmp12 and Mmp13. The present research provides new insights and prospects for studying the mechanism of thrombosis and possible drug targets.
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###### 

Modeling of DVT mice and weighing of the thrombi. (A) Inferior vena cava thrombosis. (B) Thrombi in mice with successful DVT modeling. (C) Wet weights of the mouse thrombi. After establishing a mouse inferior vena cava thrombosis model, the thrombi and vessel walls were removed from the mice in the two groups. The weights of the thrombi in the Klf15-siRNA group were significantly higher than those in the Klf15-NC group ^\*\*^P\<0.01. (D) Quantitative PCR analysis of the expression of Klf15 in the two groups. The expression of Klf15 in the Klf15-siRNA group was significantly lower than that in the Klf15-NC group. ^\*\*^P\<0.01 Klf15-NC. si, small interfering; Klf15, Krüppel-like family 15; NC, negative control; DVT, deep venous thrombosis.

![](IJMM-45-06-1735-g00)

![](IJMM-45-06-1735-g01)

![Correlation and clustering analyses for the comparison of the DVT group and the Blank group, and the comparison of the Klf15-NC group and the Klf15-siRNA group. Due to poor correlation according to Pearson\'s analysis, the Blank 1 group, DVT 1 group and Klf15-siRNA 3 group were excluded from further analyses. (A) Correlation heat map for the Blank group and DVT group. The essential threshold for further analysis was a Pearson\'s correlation R^2^≥0.8 and the results indicated that the distribution of the fragments per kilobases per million mapped reads values were consistent for all replicates in each group (R^2^≥0.8), except in the Blank 1 group. (B) Correlation heat map for the Klf15-NC and Klf15-siRNA groups. The results for the Klf15-siRNA 3 group revealed significant consistency in all replicates. (C) The clustering analysis demonstrated gene expression differences between the Blank group and DVT group. (D) The clustering analysis also demonstrated gene expression differences between the Klf15-NC group and the Klf15-siRNA group. si, small interfering; Klf15, Krüppel-like family 15; NC, negative control; DVT, deep venous thrombosis.](IJMM-45-06-1735-g02){#f2-ijmm-45-06-1735}

![Volcano plot of differentially expressed genes. Each point represents one gene that is detectable in both groups. The red points represent the significantly upregulated genes; the green points represent the significantly downregulated genes; the blue points represent genes that are expressed without a significant difference. (A) Volcano plot between the Blank group and the DVT group. (B) Volcano plot between the Klf15-NC group and the Klf15-siRNA group. si, small interfering; Klf15, Krüppel-like family 15; NC, negative control; DVT, deep venous thrombosis.](IJMM-45-06-1735-g03){#f3-ijmm-45-06-1735}

###### 

Bubble diagram and bar diagram of the DEG GO terms. Bubble diagram of the top 20 ranked GO terms of the DEGs. In the bubble diagram, the vertical axis indicates GO terms and the horizontal axis represents the enrichment factor. The sizes of dots indicate the number of genes in the GO term. In the bar diagram, GO terms were divided into three categories: The red bar represents BP, the green bar represents CC and the blue bar indicates MF. (A) Bubble diagram of the top 30 ranked DEGs from the comparison between the Blank group and the DVT group. (B) Bar diagram of GO terms from the comparison between the Blank group and the DVT group. Bubble diagram and bar diagram of the DEG GO terms. Bubble diagram of the top 20 ranked GO terms of the DEGs. In the bubble diagram, the vertical axis indicates GO terms and the horizontal axis represents the enrichment factor. The sizes of dots indicate the number of genes in the GO term. In the bar diagram, GO terms were divided into three categories: The red bar represents BP, the green bar represents CC and the blue bar indicates MF. (C) Bubble diagram of the top 30 ranked DEGs from the comparison of the Klf15-NC group and the Klf15-siRNA group. (D) Bar diagram of GO terms from the comparison of the Klf15-NC group and the Klf15-siRNA group. si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis; GO, gene ontology; BP, Biological process; MF, molecular function; CC, cellular component; DEGs, differentially expressed genes.
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###### 

Bar diagram and bubble diagram of KEGG pathway enrichment analysis of DEGs. In the bar diagram, KEGG pathways are listed in the order of the enrichment ratio. A bubble diagram of the top 20 ranked KEGG pathways of DEGs. In the bubble diagram, the vertical axis indicates the KEGG pathways and the horizontal axis represents the enrichment ratio. The sizes of the dots indicate the number of genes in the Gene Ontology term. (A) Bar diagram of KEGG pathways from the comparison between the Blank group and the DVT group. (B) Bubble diagram of the top 20 ranked KEGG pathways from the comparison between the Blank group and the DVT group. Bar diagram and bubble diagram of KEGG pathway enrichment analysis of DEGs. In the bar diagram, KEGG pathways are listed in the order of the enrichment ratio. A bubble diagram of the top 20 ranked KEGG pathways of DEGs. In the bubble diagram, the vertical axis indicates the KEGG pathways and the horizontal axis represents the enrichment ratio. The sizes of the dots indicate the number of genes in the Gene Ontology term. (C) Bar diagram of KEGG pathways from the comparison between the Klf15-NC group and the Klf15-siRNA group. (D) Bubble diagram of the top 20 ranked KEGG pathways from the comparison between the Klf15-NC group and the Klf15-siRNA group. si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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![Quantitative PCR analysis of the expression of 7 differentially expressed genes ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001. The expression trends of the detected genes were consistent with those obtained by RNA-sequencing, including the upregulated genes (Mmp13, Mmp12, Mmp19, Arg1, Hmox1 and Fmo3) and downregulated gene (Klf15). (A) Compared with that in Blank group, the expression level of Klf15 decreased significantly in DVT group. ^\*\*\*^P\<0.001. (B) The expression level of Mmp12 increased significantly in DVT group than that in Blank group. ^\*\*\*^P\<0.001. (C) The expression level of Mmp13 increased significantly in DVT group than that in Blank group. ^\*\*^P\<0.01. (D) The expression level of Mmp19 increased significantly in DVT group than that in Blank group. ^\*\*\*^P\<0.001. (E) Compared with that in Blank group, the expression level of Arg1 increased significantly in DVT group. ^\*\*\*^P\<0.001. (F) Compared with that in Blank group, the expression level of Ccl2 increased significantly in DVT group. ^\*\*^P\<0.01. (G) Compared with that in Blank group, the expression level of Fmo3 increased significantly in DVT group. ^\*\*\*^P\<0.001. (H) Compared with that in Blank group, the expression level of Hmox1 increased significantly in DVT group. ^\*\*\*^P\<0.001. Klf15, Krüppel-like family 15; DVT, deep venous thrombosis.](IJMM-45-06-1735-g12){#f6-ijmm-45-06-1735}

###### 

Number of successful injection of mice and successful modeling of DVT mice.

  Group                                       Blank   DVT   Klf15-NC   Klf15-siRNA
  ------------------------------------------- ------- ----- ---------- -------------
  Sample size                                 10      10    10         10
  Number of successful injection of mice      \-      \-    9          8
  Number of successful modeling of DVT mice   \-      7     5          5

si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis.

###### 

Quality assessment of the raw RNA-sequences reads results of the sequences.

  Sample          Raw_reads   Clean_reads   Clean_bases   Error_rate   Q20     Q30     GC_pct
  --------------- ----------- ------------- ------------- ------------ ------- ------- --------
  DVT1            26177314    25683459      7.71G         0.03         97.39   92.99   50.06
  DVT2            23970627    22164628      6.65G         0.03         97.01   92.28   50.38
  DVT3            27492800    26662217      8.0G          0.03         97.55   93.50   50.96
  Blank1          30056705    27671970      8.3G          0.03         97.73   93.81   50.95
  Blank2          26587894    26131760      7.84G         0.03         97.30   92.87   50.33
  Blank3          27518969    26623013      7.99G         0.03         96.92   92.03   50.23
  Klf15-NC1       23873304    23344387      7.0G          0.02         98.19   94.79   50.64
  Klf15-NC3       31553809    31061688      9.32G         0.02         98.28   95.07   51.05
  Klf15-NC4       33418796    32815907      9.84G         0.02         98.19   94.84   51.31
  Klf15-siRNA_2   28443883    27658994      8.3G          0.02         98.18   94.81   50.36
  Klf15-siRNA_3   31256846    30573498      9.17G         0.02         98.26   94.90   51.13
  Klf15-siRNA_5   31209875    30496859      9.15G         0.02         98.05   94.40   50.41

si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis; NC, negative control.

###### 

Read mapping results of the sequences

  Sample          Total_reads   Total_map (%)      Unique_map (%)     Multi_map (%)    Splice_map (%)
  --------------- ------------- ------------------ ------------------ ---------------- ------------------
  DVT1            51366918      49046085 (95.48)   46528972 (90.58)   2517113 (4.9)    17368593 (33.81)
  DVT2            44329256      41980259 (94.7)    39085822 (88.17)   2894437 (6.53)   15925579 (35.93)
  DVT3            53324434      50898142 (95.45)   47701078 (89.45)   3197064 (6.0)    19203249 (36.01)
  Blank1          55343940      53021663 (95.8)    49481609 (89.41)   3540054 (6.4)    20032572 (36.2)
  Blank2          52263520      49811834 (95.31)   47560000 (91.0)    2251834 (4.31)   18114051 (34.66)
  Blank3          53246026      50413825 (94.68)   48052390 (90.25)   2361435 (4.43)   18879029 (35.46)
  Klf15-NC1       46688774      45469186 (97.39)   42152166 (90.28)   3317020 (7.1)    16922773 (36.25)
  Klf15-NC3       62123376      60297028 (97.06)   55302462 (89.02)   4994566 (8.04)   21761027 (35.03)
  Klf15-NC4       65631814      63630957 (96.95)   58085965 (88.5)    5544992 (8.45)   23699020 (36.11)
  Klf15-siRNA_2   55317988      53743158 (97.15)   50929624 (92.07)   2813534 (5.09)   19622245 (35.47)
  Klf15-siRNA_3   61146996      59683848 (97.61)   53836311 (88.04)   5847537 (9.56)   22426460 (36.68)
  Klf15-siRNA_5   60993718      59329105 (97.27)   55020590 (90.21)   4308515 (7.06)   21394177 (35.08)

si, small interfering; Klf15, Krüppel-like family 15; NC, negative control; DEG, differentially expressed genes; DVT, deep venous thrombosis.

###### 

The number of DEGs identified from four groups.

  DEG set             DEGs    Upregulated   Downregulated
  ------------------- ------- ------------- ---------------
  DVT_vs_Blank        2,206   1,330         876
  Klf15-siRNA_vs_NC   1,041   235           806

si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis; NC, negative control; DEG, differentially expressed genes.

###### 

DEGs identified in a comparison of the DVT group and the Blank group by RNA-sequencing.

  Gene_id              DVT         Blank      log2 Fold change   Padj            Gene_name
  -------------------- ----------- ---------- ------------------ --------------- -----------
  ENSMUSG00000049723   78.077668   47.9396    0.707139           0.566752        Mmp12
  ENSMUSG00000050578   204.5046    4.875547   5.391707           3.03×10^−09^    Mmp13
  ENSMUSG00000043613   3941.1668   290.8774   3.759948           3.10×10^−39^    Mmp3
  ENSMUSG00000005800   3114.6048   63.94969   5.606005           1.10×10^−10^    Mmp8
  ENSMUSG00000017737   7694.2132   732.7235   3.392543           1.06×10^−29^    Mmp9
  ENSMUSG00000025355   1703.9523   203.5787   3.064868           1.52×10^−13^    Mmp19
  ENSMUSG00000026073   3607.8063   48.75941   6.20899            3.12×10^−63^    Il1r2
  ENSMUSG00000027399   553.44397   39.4537    3.811049           9.93×10^−19^    Il1a
  ENSMUSG00000027398   5679.7852   139.7907   5.344781           9.60×10^−76^    Il1b
  ENSMUSG00000025746   1369.395    5.758426   7.893124           2.59×10^−39^    Il6
  ENSMUSG00000035352   906.99266   100.0886   3.17938            6.97×10^−21^    Ccl12
  ENSMUSG00000035385   3020.6374   95.41017   4.984662           1.14×10^−08^    Ccl2
  ENSMUSG00000094686   7.4708094   119.9455   −4.02534           2.10×10^−06^    Ccl21a
  ENSMUSG00000000982   3120.6479   31.87038   6.61243            3.97×10^−76^    Ccl3
  ENSMUSG00000018930   1205.0351   32.31576   5.220409           1.03×10^−32^    Ccl4
  ENSMUSG00000035042   712.57684   2817.25    −1.98337           1.21×10^−11^    Ccl5
  ENSMUSG00000018927   8371.4662   1210.417   2.789986           1.64×10^−44^    Ccl6
  ENSMUSG00000035373   2485.7371   79.30941   4.970069           3.32×10^−07^    Ccl7
  ENSMUSG00000019122   5063.0309   592.4913   3.095273           2.35×10^−50^    Ccl9
  ENSMUSG00000029380   2017.182    19.95151   6.659775           1.9×10^−104^    Cxcl1
  ENSMUSG00000061353   6200.4582   10594.49   −0.77288           4.82×10^−05^    Cxcl12
  ENSMUSG00000021508   3590.1969   118.9011   4.916188           6.83×10^−07^    Cxcl14
  ENSMUSG00000018920   523.29727   975.7794   −0.89848           0.00284         Cxcl16
  ENSMUSG00000058427   16451.23    10.20436   10.65536           8.05×10^−148^   Cxcl2
  ENSMUSG00000029379   9750.5765   0.886821   13.4245            9.92×10^−35^    Cxcl3
  ENSMUSG00000029371   3329.7922   4.430165   9.552655           7.59×10^−79^    Cxcl5
  ENSMUSG00000029417   721.6049    682.6357   0.079769           0.889672        Cxcl9
  ENSMUSG00000026180   3454.5181   333.2202   3.3741             5.89×10^−46^    Cxcr2
  ENSMUSG00000045382   3109.524    812.4151   1.93664            2.84×10^−15^    Cxcr4
  ENSMUSG00000048521   152.50759   568.3105   −1.89793           1.83×10^−07^    Cxcr6
  ENSMUSG00000026691   114.11276   14.20097   3.004407           0.005941        Fmo3
  ENSMUSG00000026580   1733.686    129.0424   3.747548           5.07×10^−28^    Selp
  ENSMUSG00000046223   3734.2897   435.4963   3.100282           1.12×10^−47^    Plaur
  ENSMUSG00000005413   12311.935   735.4273   4.065414           7.15×10^−42^    Hmox1
  ENSMUSG00000019987   9944.886    38.99255   7.994212           1.56×10^−176^   Arg1

si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis.

###### 

Differentially expressed genes identified in a comparison of the Klf15-siRNA group and the Klf15-NC group.

  Gene_id              siRNA       NC         log2 Fold change   Padj           Gene_name
  -------------------- ----------- ---------- ------------------ -------------- -----------
  ENSMUSG00000030087   100.70496   301.1934   −1.58155           0.000497       Klf15
  ENSMUSG00000049723   647.4817    101.9324   2.665213           6.61×10^−05^   Mmp12
  ENSMUSG00000050578   401.39705   115.9458   1.796271           0.000549       Mmp13

si, small interfering; Klf15, Krüppel-like family 15; NC, negative control.

###### 

KEGG pathway enrichment analysis of the DVT group vs. the Blank group.

  KEGGID     Description                                    Gene ratio   BgRatio    P-value        Count   Up   Down
  ---------- ---------------------------------------------- ------------ ---------- -------------- ------- ---- ------
  mmu04060   Cytokine-cytokine receptor interaction         100/907      234/6352   2.48×10^−27^   100     60   40
  mmu04640   Hematopoietic cell lineage                     50/907       89/6352    1.65×10^−20^   50      26   24
  mmu05323   Rheumatoid arthritis                           30/907       77/6352    7.01×10^−08^   30      21   9
  mmu05144   Malaria                                        22/907       47/6352    8.39×^−08^     22      20   2
  mmu04066   HIF-1 signaling pathway                        34/907       99/6352    3.48×10^−07^   34      31   3
  mmu04659   Th17 cell differentiation                      34/907       99/6352    3.48×10^−07^   34      13   21
  mmu04672   Intestinal immune network for IgA production   19/907       41/6352    7.86×10^−07^   19      4    15
  mmu04668   TNF signaling pathway                          35/907       107/6352   8.86×10^−07^   35      32   3
  mmu04514   Cell adhesion molecules                        42/907       146/6352   3.46×10^−06^   42      18   24
  mmu04151   PI3K-Akt signaling pathway                     75/907       319/6352   4.15×10^−06^   75      51   24
  mmu04512   ECM-receptor interaction                       28/907       82/6352    4.28×10^−06^   28      19   9
  mmu04657   IL-17 signaling pathway                        29/907       87/6352    5.01×10^−06^   29      27   2
  mmu00010   Glycolysis/gluconeogenesis                     23/907       62/6352    6.36×10^−06^   23      19   4
  mmu04380   Osteoclast differentiation                     36/907       123/6352   1.13×10^−05^   36      34   2
  mmu05140   Leishmaniasis                                  23/907       65/6352    1.58×10^−05^   23      17   6
  mmu05150   Staphylococcus aureus infection                18/907       45/6352    1.95×10^−05^   18      12   6
  mmu04658   Th1 and Th2 cell differentiation               27/907       85/6352    2.85×10^−05^   27      7    20
  mmu04610   Complement and coagulation cascades            24/907       73/6352    4.20×10^−05^   24      19   5
  mmu05321   Inflammatory bowel disease                     20/907       57/6352    6.44×10^−05^   20      10   10
  mmu04630   Jak-STAT signaling pathway                     38/907       143/6352   7.05×10^−05^   38      25   13
  mmu05152   Tuberculosis                                   41/907       160/6352   9.04×10^−05^   41      29   12
  mmu04064   NF-κB signaling pathway                        27/907       92/6352    0.0001319      27      16   11
  mmu05340   Primary immunodeficiency                       14/907       35/6352    0.0001645      14      0    14
  mmu05202   Transcriptional misregulation in cancer        41/907       169/6352   0.0003243      41      27   14
  mmu05162   Measles                                        32/907       122/6352   0.0003335      32      19   13
  mmu04010   MAPK signaling pathway                         61/907       281/6352   0.0003692      61      49   12
  mmu05166   HTLV-I infection                               57/907       262/6352   0.0005396      57      31   26
  mmu05164   Influenza A                                    36/907       147/6352   0.0006105      36      27   9
  mmu00052   Galactose metabolism                           12/907       31/6352    0.0006857      12      11   1
  mmu05418   Fluid shear stress and atherosclerosis         34/907       138/6352   0.0007639      34      31   3
  mmu05320   Autoimmune thyroid disease                     16/907       50/6352    0.0010955      16      6    10
  mmu00220   Arginine biosynthesis                          8/907        17/6352    0.001229       8       6    2
  mmu05145   Toxoplasmosis                                  27/907       105/6352   0.0013127      27      15   12
  mmu04062   Chemokine signaling pathway                    40/907       176/6352   0.0015037      40      27   13
  mmu04216   Ferroptosis                                    13/907       39/6352    0.0020876      13      11   2
  mmu04612   Antigen processing and presentation            20/907       74/6352    0.0028603      20      9    11
  mmu05332   Graft-versus-host disease                      15/907       50/6352    0.0031691      15      7    8
  mmu05133   Pertussis                                      19/907       70/6352    0.0034227      19      17   2
  mmu04145   Phagosome                                      35/907       156/6352   0.0036189      35      25   10
  mmu04621   NOD-like receptor signaling pathway            34/907       151/6352   0.0038603      34      30   4
  mmu05134   Legionellosis                                  16/907       56/6352    0.0040295      16      15   1
  mmu00590   Arachidonic acid metabolism                    17/907       61/6352    0.0040877      17      14   3
  mmu04620   Toll-like receptor signaling pathway           22/907       87/6352    0.0044241      22      19   3
  mmu05230   Central carbon metabolism in cancer            17/907       62/6352    0.0049021      17      16   1
  mmu05330   Allograft rejection                            14/907       48/6352    0.0056832      14      4    10
  mmu04940   Type I diabetes mellitus                       15/907       53/6352    0.0058193      15      6    9
  mmu04931   Insulin resistance                             25/907       105/6352   0.0058616      25      18   7
  mmu05310   Asthma                                         8/907        21/6352    0.0060726      8       1    7
  mmu05142   Chagas disease (American trypanosomiasis)      24/907       100/6352   0.0061752      24      18   6
  mmu01230   Biosynthesis of amino acids                    18/907       70/6352    0.0079558      18      15   3

KEGG, Kyoto Encyclopedia of Genes and Genomes; DVT, deep venous thrombosis.

###### 

KEGG Pathways enrichment analysis of KLF15-siRNA group vs. KLF15-NC group.

  KEGGID     Description                               Gene ratio   BgRatio    P-value        Count   Up   Down
  ---------- ----------------------------------------- ------------ ---------- -------------- ------- ---- ------
  mmu04514   Cell adhesion molecules                   25/352       144/6351   2.50×10^−07^   25      8    17
  mmu04725   Cholinergic synapse                       20/352       107/6351   1.23×10^−06^   20      0    20
  mmu04080   Neuroactive ligand-receptor interaction   30/352       225/6351   5.42×10^−06^   30      3    27
  mmu04512   ECM-receptor interaction                  15/352       82/6351    3.52×10^−05^   15      0    15
  mmu04728   Dopaminergic synapse                      19/352       126/6351   5.60×10^−05^   19      0    19
  mmu05033   Nicotine addiction                        8/352        35/6351    0.0005167      8       0    8
  mmu05323   Rheumatoid arthritis                      12/352       76/6351    0.0008645      12      8    4
  mmu04151   PI3K-Akt signaling pathway                32/352       325/6351   0.0009717      32      5    27
  mmu04721   Synaptic vesicle cycle                    10/352       59/6351    0.0013226      10      1    9
  mmu04742   Taste transduction                        9/352        50/6351    0.0014766      9       0    9
  mmu04270   Vascular smooth muscle contraction        15/352       115/6351   0.0015912      15      1    14
  mmu05410   Hypertrophic cardiomyopathy               12/352       82/6351    0.0017112      12      1    11
  mmu04390   Hippo signaling pathway                   18/352       152/6351   0.0017475      18      1    17
  mmu04726   Serotonergic synapse                      14/352       106/6351   0.0020024      14      0    14
  mmu00512   Mucin type O-glycan biosynthesis          6/352        26/6351    0.0024822      6       1    5
  mmu05414   Dilated cardiomyopathy                    12/352       86/6351    0.0025876      12      0    12
  mmu04024   cAMP signaling pathway                    20/352       186/6351   0.003181       20      0    20
  mmu05321   Inflammatory bowel disease                9/352        56/6351    0.003331       9       7    2
  mmu04974   Protein digestion and absorption          11/352       78/6351    0.0035469      11      2    9
  mmu05144   Malaria                                   8/352        47/6351    0.0038607      8       2    6
  mmu04727   GABAergic synapse                         11/352       79/6351    0.0039219      11      0    11
  mmu04911   Insulin secretion                         11/352       79/6351    0.0039219      11      1    10
  mmu04926   Relaxin signaling pathway                 15/352       126/6351   0.0039259      15      1    14

KEGG, Kyoto Encyclopedia of Genes and Genomes; DVT, deep venous thrombosis; si, small interfering; NC, negative control.

[^1]: Contributed equally
